
    
      Up to five panels (Panels A-E) of 6 participants each will be enrolled in a sequential
      manner. In each panel, participants will receive a single dose of MK-8527 up to 50 mg.
      Historical data from previous single does studies will be used for placebo (control)
      comparisons.
    
  